Motion Sickness
5
Pipeline Programs
1
Companies
4
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
VP
Competitive Landscape
1 companies ranked by most advanced pipeline stage
VP
Vanda PharmaceuticalsWASHINGTON, DC
4 programs1
3
1
TradipitantPhase 31 trial
TradipitantPhase 31 trial
TradipitantPhase 31 trial
TradipitantPhase 21 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Vanda PharmaceuticalsTradipitant
Vanda PharmaceuticalsTradipitant
Vanda PharmaceuticalsTradipitant
Vanda PharmaceuticalsTradipitant
Clinical Trials (4)
Total enrollment: 1,513 patients across 4 trials
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Start: Sep 2023Est. completion: Apr 2024316 patients
Phase 3Completed
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Start: Feb 2023Est. completion: Jun 2026705 patients
Phase 3Active Not Recruiting
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Start: Nov 2021Est. completion: Apr 2023366 patients
Phase 3Completed
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Start: Dec 2018Est. completion: Jun 2019126 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space